However, the first targeted agent for bladder cancer, erdafitinib, is active and is approved to treat postplatinum patients with activating somatic FGFR2/3 mutations or fusions, which are seen in approximately 15% of patients (40). This evidence concerns the gene FGFR2 and urinary bladder carcinoma.